O	0	6	Effect
O	7	9	of
O	10	24	bisphosphonate
O	25	28	use
O	29	31	on
O	32	36	risk
O	37	39	of
O	40	54	postmenopausal
O	55	61	breast
O	62	68	cancer
O	68	69	:
O	70	77	results
O	78	82	from
O	83	86	the
O	87	97	randomized
O	98	106	clinical
O	107	113	trials
O	114	116	of
B-intervention	117	128	alendronate
I-intervention	129	132	and
I-intervention	133	143	zoledronic
I-intervention	144	148	acid
O	148	149	.

O	150	157	Studies
O	158	162	have
O	163	168	shown
O	169	173	that
O	174	189	bisphosphonates
O	190	193	may
O	194	198	have
O	199	208	antitumor
O	209	212	and
O	213	227	antimetastatic
O	228	238	properties
O	238	239	.

O	240	248	Recently
O	248	249	,
O	250	263	observational
O	264	271	studies
O	272	276	have
O	277	286	suggested
O	287	288	a
O	289	297	possible
O	298	308	protective
O	309	315	effect
O	316	318	of
O	319	334	bisphosphonates
O	335	337	on
O	338	344	breast
O	345	351	cancer
O	351	352	,
O	353	356	but
O	357	360	the
O	361	367	effect
O	368	370	of
O	371	385	bisphosphonate
O	386	389	use
O	390	392	on
O	393	397	risk
O	398	400	of
O	401	407	breast
O	408	414	cancer
O	415	418	has
O	419	422	not
O	423	427	been
O	428	434	tested
O	435	437	in
O	438	448	randomized
O	449	455	trials
O	455	456	.

O	457	459	To
O	460	466	assess
O	467	470	the
O	471	483	relationship
O	484	486	of
O	487	501	postmenopausal
O	502	508	breast
O	509	515	cancer
O	516	525	incidence
O	526	529	and
O	530	544	bisphosphonate
O	545	548	use
O	549	554	using
O	555	559	data
O	560	564	from
O	565	566	2
O	567	577	randomized
O	578	579	(
O	579	580	1
O	580	581	:
O	581	582	1
O	582	583	)
O	583	584	,
O	585	591	double
O	591	592	-
O	592	597	blind
O	597	598	,
O	599	606	placebo
O	606	607	-
O	607	617	controlled
O	618	624	trials
O	624	625	.

O	626	629	The
O	630	638	Fracture
O	639	651	Intervention
O	652	657	Trial
O	658	659	(
O	659	662	FIT
O	662	663	)
O	664	672	randomly
O	673	681	assigned
B-total-participants	682	686	6459
O	687	692	women
O	693	697	aged
B-age	698	700	55
I-age	701	703	to
I-age	704	706	81
I-age	707	712	years
O	713	715	to
O	716	727	alendronate
O	728	730	or
B-control	731	738	placebo
O	739	742	for
O	743	744	a
O	745	749	mean
O	750	756	follow
O	756	757	-
O	757	759	up
O	760	762	of
O	763	764	3
O	764	765	.
O	765	766	8
O	767	772	years
O	772	773	.

O	774	777	The
O	778	784	Health
O	785	793	Outcomes
O	794	797	and
O	798	805	Reduced
O	806	815	Incidence
O	816	820	With
O	821	831	Zoledronic
O	832	836	Acid
O	837	841	Once
O	842	848	Yearly
O	848	849	-
O	849	856	Pivotal
O	857	865	Fracture
O	866	871	Trial
O	872	873	(
O	873	880	HORIZON
O	880	881	-
O	881	884	PFT
O	884	885	)
O	886	894	randomly
O	895	903	assigned
B-total-participants	904	908	7765
O	909	914	women
O	915	919	aged
O	920	922	65
O	923	925	to
O	926	928	89
O	929	934	years
O	935	937	to
O	938	944	annual
O	945	956	intravenous
O	957	967	zoledronic
O	968	972	acid
O	973	975	or
O	976	983	placebo
O	984	987	for
O	988	989	a
O	990	994	mean
O	995	1001	follow
O	1001	1002	-
O	1002	1004	up
O	1005	1007	of
O	1008	1009	2
O	1009	1010	.
O	1010	1011	8
O	1012	1017	years
O	1017	1018	.

O	1019	1023	Data
O	1024	1028	were
O	1029	1038	collected
O	1039	1041	at
O	1042	1050	clinical
O	1051	1058	centers
O	1059	1061	in
O	1062	1065	the
O	1066	1072	United
O	1073	1079	States
O	1080	1081	(
O	1081	1084	FIT
O	1085	1088	and
O	1089	1096	HORIZON
O	1096	1097	-
O	1097	1100	PFT
O	1100	1101	)
O	1102	1105	and
O	1106	1108	in
B-location	1109	1113	Asia
I-location	1114	1117	and
I-location	1118	1121	the
I-location	1122	1129	Pacific
I-location	1129	1130	,
I-location	1131	1137	Europe
I-location	1137	1138	,
I-location	1139	1144	North
I-location	1145	1152	America
I-location	1152	1153	,
I-location	1154	1157	and
I-location	1158	1163	South
I-location	1164	1171	America
O	1172	1173	(
O	1173	1180	HORIZON
O	1180	1181	-
O	1181	1184	PFT
O	1184	1185	)
O	1185	1186	.

O	1187	1192	Women
O	1192	1193	,
O	1194	1196	in
O	1197	1203	either
O	1204	1209	study
O	1209	1210	,
O	1211	1215	with
O	1216	1225	recurrent
O	1226	1232	breast
O	1233	1239	cancer
O	1240	1242	or
O	1243	1246	who
O	1247	1255	reported
O	1256	1257	a
O	1258	1265	history
O	1266	1268	of
O	1269	1275	breast
O	1276	1282	cancer
O	1283	1287	were
O	1288	1296	excluded
O	1297	1301	from
O	1302	1310	analyses
O	1310	1311	.

O	1312	1314	In
O	1315	1319	each
O	1320	1325	trial
O	1325	1326	,
O	1327	1328	a
O	1329	1336	blinded
O	1337	1343	review
O	1344	1347	was
O	1348	1357	conducted
O	1358	1360	of
O	1361	1365	each
O	1366	1372	cancer
O	1373	1380	adverse
O	1381	1386	event
O	1387	1393	report
O	1394	1396	to
O	1397	1403	verify
O	1404	1412	incident
O	1413	1421	invasive
O	1422	1428	breast
O	1429	1435	cancer
O	1436	1441	cases
O	1441	1442	.

O	1443	1446	The
O	1447	1454	primary
O	1455	1463	analysis
O	1464	1472	compared
O	1473	1479	events
O	1480	1482	in
O	1483	1486	the
O	1487	1493	active
O	1494	1496	vs
O	1497	1504	placebo
O	1505	1510	group
O	1511	1516	using
O	1517	1518	a
O	1519	1522	log
O	1522	1523	-
O	1523	1527	rank
O	1528	1532	test
O	1532	1533	.

O	1534	1545	Alendronate
O	1546	1548	vs
O	1549	1556	placebo
O	1557	1558	(
O	1558	1561	FIT
O	1561	1562	)
O	1563	1565	or
O	1566	1576	zoledronic
O	1577	1581	acid
O	1582	1584	vs
O	1585	1592	placebo
O	1593	1594	(
O	1594	1601	HORIZON
O	1601	1602	-
O	1602	1605	PFT
O	1605	1606	)
O	1606	1607	.

O	1608	1614	Hazard
O	1615	1620	ratio
O	1621	1624	for
B-outcome	1625	1633	incident
I-outcome	1634	1640	breast
I-outcome	1641	1647	cancer
O	1648	1650	in
O	1651	1654	the
O	1655	1669	bisphosphonate
O	1670	1679	treatment
O	1680	1685	group
O	1686	1694	compared
O	1695	1697	to
O	1698	1701	the
O	1702	1709	placebo
O	1710	1715	group
O	1715	1716	.

O	1717	1722	There
O	1723	1726	was
O	1727	1729	no
O	1730	1741	significant
O	1742	1752	difference
O	1753	1755	in
O	1756	1759	the
B-outcome	1760	1764	rate
I-outcome	1765	1767	of
I-outcome	1768	1774	breast
I-outcome	1775	1781	cancer
O	1782	1784	in
O	1785	1788	FIT
O	1788	1789	:
B-cv-bin-percent	1790	1791	1
I-cv-bin-percent	1791	1792	.
I-cv-bin-percent	1792	1793	5
I-cv-bin-percent	1793	1794	%
O	1795	1796	(
O	1796	1797	n
O	1798	1799	=
B-cv-bin-abs	1800	1802	46
O	1802	1803	)
O	1804	1806	in
O	1807	1810	the
O	1811	1818	placebo
O	1819	1824	group
O	1825	1828	and
B-iv-bin-percent	1829	1830	1
I-iv-bin-percent	1830	1831	.
I-iv-bin-percent	1831	1832	8
I-iv-bin-percent	1832	1833	%
O	1834	1835	(
O	1835	1836	n
O	1837	1838	=
B-iv-bin-abs	1839	1841	57
O	1841	1842	)
O	1843	1845	in
O	1846	1849	the
O	1850	1861	alendronate
O	1862	1867	group
O	1868	1869	(
O	1869	1875	hazard
O	1876	1881	ratio
O	1882	1883	[
O	1883	1885	HR
O	1885	1886	]
O	1886	1887	,
O	1888	1889	1
O	1889	1890	.
O	1890	1892	24
O	1893	1894	[
O	1894	1896	95
O	1896	1897	%
O	1898	1900	CI
O	1900	1901	,
O	1902	1903	0
O	1903	1904	.
O	1904	1906	84
O	1906	1907	-
O	1907	1908	1
O	1908	1909	.
O	1909	1911	83
O	1911	1912	]
O	1912	1913	)
O	1913	1914	.

O	1915	1917	In
O	1918	1925	HORIZON
O	1925	1926	-
O	1926	1929	PFT
O	1929	1930	,
O	1931	1936	there
O	1937	1940	was
O	1941	1945	also
O	1946	1948	no
O	1949	1960	significant
O	1961	1971	difference
O	1971	1972	:
B-cv-bin-percent	1973	1974	0
I-cv-bin-percent	1974	1975	.
I-cv-bin-percent	1975	1976	8
I-cv-bin-percent	1976	1977	%
O	1978	1979	(
O	1979	1980	n
O	1981	1982	=
O	1983	1985	29
O	1985	1986	)
O	1987	1989	in
O	1990	1993	the
O	1994	2001	placebo
O	2002	2007	group
O	2008	2011	and
B-iv-bin-percent	2012	2013	0
I-iv-bin-percent	2013	2014	.
I-iv-bin-percent	2014	2015	9
I-iv-bin-percent	2015	2016	%
O	2017	2018	(
O	2018	2019	n
O	2020	2021	=
O	2022	2024	33
O	2024	2025	)
O	2026	2028	in
O	2029	2032	the
O	2033	2043	zoledronic
O	2044	2048	acid
O	2049	2054	group
O	2055	2056	(
O	2056	2058	HR
O	2058	2059	,
O	2060	2061	1
O	2061	2062	.
O	2062	2064	15
O	2065	2066	[
O	2066	2068	95
O	2068	2069	%
O	2070	2072	CI
O	2072	2073	,
O	2074	2075	0
O	2075	2076	.
O	2076	2078	70
O	2078	2079	-
O	2079	2080	1
O	2080	2081	.
O	2081	2083	89
O	2083	2084	]
O	2084	2085	)
O	2085	2086	.

O	2087	2092	There
O	2093	2096	was
O	2097	2101	also
O	2102	2104	no
O	2105	2116	significant
O	2117	2127	difference
O	2128	2132	when
O	2133	2136	the
O	2137	2141	data
O	2142	2146	from
O	2147	2150	FIT
O	2151	2154	and
O	2155	2162	HORIZON
O	2162	2163	-
O	2163	2166	PFT
O	2167	2171	were
O	2172	2178	pooled
O	2179	2180	(
O	2180	2182	HR
O	2182	2183	,
O	2184	2185	1
O	2185	2186	.
O	2186	2188	20
O	2189	2190	[
O	2190	2192	95
O	2192	2193	%
O	2194	2196	CI
O	2196	2197	,
O	2198	2199	0
O	2199	2200	.
O	2200	2202	89
O	2202	2203	-
O	2203	2204	1
O	2204	2205	.
O	2205	2207	63
O	2207	2208	]
O	2208	2209	)
O	2209	2210	.

O	2211	2216	These
O	2217	2218	2
O	2219	2229	randomized
O	2230	2238	clinical
O	2239	2245	trials
O	2246	2248	do
O	2249	2252	not
O	2253	2260	support
O	2261	2264	the
O	2265	2273	findings
O	2274	2278	from
O	2279	2292	observational
O	2293	2301	research
O	2301	2302	.

O	2303	2311	Contrary
O	2312	2314	to
O	2315	2318	the
O	2319	2326	results
O	2327	2331	from
O	2332	2345	observational
O	2346	2353	studies
O	2353	2354	,
O	2355	2357	we
O	2358	2363	found
O	2364	2368	that
O	2369	2370	3
O	2371	2373	to
O	2374	2375	4
O	2376	2381	years
O	2382	2384	of
O	2385	2399	bisphosphonate
O	2400	2409	treatment
O	2410	2413	did
O	2414	2417	not
O	2418	2426	decrease
O	2427	2430	the
O	2431	2435	risk
O	2436	2438	of
O	2439	2447	invasive
O	2448	2462	postmenopausal
O	2463	2469	breast
O	2470	2476	cancer
O	2476	2477	.
O	2478	2492	clinicaltrials
O	2492	2493	.
O	2493	2496	gov
O	2497	2507	Identifier
O	2507	2508	:
O	2509	2520	NCT00049829
O	2521	2522	(
O	2522	2529	HORIZON
O	2529	2530	-
O	2530	2533	PFT
O	2533	2534	)
O	2534	2535	.
